Your Article Summary
See Latest ArticlesFDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder
GlaxoSmithKline, 11/21/08
GlaxoSmithKline announced that the United States Food and Drug Administration (FDA) granted accelerated approval for Promacta (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The approval is a significant milestone for eltrombopag and the ITP community, as eltrombopag is the first oral thrombopoietin (TPO) receptor agonist approved for adult patients with chronic ITP. GSK expects eltrompopag to be available next week.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09